Methods of obtaining (from cadaveric human brain) the highly-active extracts to be used later as raw-materials for thromboplastin manufacturing, which is applied to determine the prothrombin (thromboplastin) time of human plasma or blood, are described in the paper. The study resulted in defining the optimal requirements to choosing the raw-materials, storing regime, centrifuging and extraction. The thus elaborated technology of soluble thromboplastin manufacturing ensures the production of a reagent with a high sensitivity to a changing level of factors VII and X and to a reducing activity of the prothrombin complex, which is achieved through the impact of indirect anticoagulants.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a whole blood point-of-care coagulation analyzer in dogs.
J Vet Emerg Crit Care (San Antonio)
October 2024
Department of Emergency and Critical Care, University of Georgia, Athens, Georgia, USA.
Objective: To compare the accuracy of a point-of-care coagulation analyzer (POCCA) with a reference laboratory coagulation analyzer (LabCA) and to evaluate for confounding factors that could alter the performance of the POCCA.
Design: Prospective, observational study.
Setting: Two university veterinary teaching hospitals.
Effects of heterogeneous surface characteristics on hemocompatibility and cytocompatibility of bacterial nanocellulose.
Carbohydr Polym
July 2024
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, Donghua University, Shanghai, China; College of Biological Science and Medical Engineering, Donghua University, Shanghai, China; National Advanced Functional Fiber Innovation Center, Wu Jiang, Su Zhou, China; Scientific Research Base of Bacterial Nanofiber Manufacturing and Composite Technology, China Textile Engineering Society, China. Electronic address:
The surface properties of cardiovascular biomaterials play a critical role in their biological responses. Although bacterial nanocellulose (BNC) materials have exhibited potential applications in cardiovascular implants, the impact of their surface characteristics on biocompatibility has rarely been studied. This study investigated the mechanism for the biocompatibility induced by the physicochemical properties of both sides of BNC.
View Article and Find Full Text PDFImpact of systematic variations in hematocrit and platelet count on thrombelastometry tissue factor activated assay parameters.
Transfusion
May 2024
Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Background: Thromboelastogram testing is increasingly being used to manage patients with massive bleeding. An earlier study found that the test results were influenced by the hematocrit (Hct) and platelet (PLT) concentrations. This study sought to determine if these factors confounded the results of a different manufacturer's thromboelastography testing.
View Article and Find Full Text PDFDetermination of procoagulant activity in human normal immunoglobulin preparations for therapeutic use by FXIa chromogenic assay: Evaluation of test kit sensitivity, reference standard performance and product formulation effects on the FXIa assay.
Pharmeur Bio Sci Notes
March 2024
Paul-Ehrlich-Institute, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany.
In 2010, the reporting of thrombotic adverse events for one subcutaneous and certain intravenous immunoglobulins (IGs) raised some concerns. In Europe, regulatory bodies rapidly revised compendial specifications for therapeutic IGs to ensure they do not exhibit thrombogenic (procoagulant) activity (PCA). At the global level, a working group (GWG) was launched with the aim of assessing PCA measurement methods and limits, considering results obtained by human IG manufacturers during in-process controls.
View Article and Find Full Text PDFVariability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
Int J Lab Hematol
August 2024
Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
Introduction: An investigation of the suitability of reagents for measuring FVIII products in a one-stage clotting assay (OSA) showed variations in their FVIII activity (FVIII:C). Most studies have focused on the activated partial thromboplastin time (APTT) reagent rather than FVIII-deficient plasma (F8DP), even though the APTT-based OSA is comprised of APTT reagents and factor-deficient plasma.
Aim: A single-centre study was conducted to clarify variations in measurements of FVIII products in an OSA using a total of 12 reagent combinations, including four APTT reagents and three types of F8DP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!